Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT00141700
Phase
PHASE2
Status
Terminated

Conditions

  • Lymphoma, Non-Hodgkin's

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, stem cell support and Rituximab (which is a form of immunotherapy).

Key Dates

Start date
Mar 31, 2003
Status verified
Dec 2007
Primary completion
Mar 31, 2005
Completion
Dec 31, 2005

Study Design

Enrollment
30 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Assess progression-free survival after rituximab and high-dose chemotherapy with autologous PBPC support;

Locations (1)

FacilityCityStateZIPSite coordinators
The University of MichiganAnn ArborMichigan48109-

Find similar trials in Ann Arbor, MI

By research site
The University of Michigan· Ann Arbor, MI

Related Studies